Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Immutep Ltd ( (AU:IMM) ) is now available.
Immutep Limited has successfully completed the FDA’s Project Optimus requirements, confirming 30 mg as the optimal biological dose for its immunotherapy candidate efti, which is significant for its oncology pipeline and future Biological License Applications. This development is strategically important for Immutep’s ongoing and future clinical trials, including the Phase III TACTI-004 trial for non-small cell lung cancer, positioning the company to advance its novel immunotherapy to market and address global cancer patient needs.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. It is a leader in the development of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), with a diverse product portfolio aimed at stimulating or suppressing the immune response to provide innovative treatments and maximize shareholder value.
YTD Price Performance: -16.44%
Average Trading Volume: 2,504,757
Technical Sentiment Signal: Hold
Current Market Cap: A$448.9M
For an in-depth examination of IMM stock, go to TipRanks’ Overview page.